Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 6/20 | 0.52 |
| ▸ | METAP2 | P50579 | 3/20 | 0.36 |
| ▸ | AXL | P30530 | 2/20 | 0.33 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.33 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.33 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.32 |
| ▸ | PLK4 | O00444 | 1/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | CSF1R | P07333 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.32 |
| ▸ | LTK | P29376 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20177012 | 0.83 | NOS1 (0.46) | NOS1METAP2AXLIDO1 | |
| Ammonia Solution, Strong SCHEMBL28854543 | 0.81 | NOS1 (0.44) | NOS1METAP2AXLIDO1 | |
| SCHEMBL358061 | 0.68 | NOS1 (1.00) | NOS1METAP2AXLCDK2IDO1 | |
| SCHEMBL2598373 | 0.67 | MAPKAPK2 (0.38) | NOS1METAP2PTK2CSNK1A1HTT | |
| SCHEMBL29506132 | 0.67 | NOS1 (0.47) | NOS1CCNT1CCNA2CDK2CDK9 | |
| SCHEMBL22160446 | 0.66 | NOS1 (0.55) | NOS1METAP2AXLCCNA2CDK2 | |
| SCHEMBL22553827 | 0.63 | NOS1 (0.43) | NOS1 | |
| SCHEMBL29803170 | 0.62 | MAPT (0.39) | NOS1METAP2AXLCDK2PTK2 | |
| SCHEMBL21733358 | 0.62 | MAPT (0.47) | NOS1PTK2PLK4CHEK1AURKA | |
| SCHEMBL21733576 | 0.62 | MAPT (0.43) | NOS1METAP2CDK2PTK2PLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2603504-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2013-06-19 | — | — | EP | disclosed |
| US-20120195857-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-02 | — | — | US | disclosed |
| US-20120195857-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-02 | — | — | US | disclosed |
| WO-2012021591-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-16 | — | — | WO | disclosed |
| WO-2012021591-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-16 | — | — | WO | disclosed |
| US-4096333-A | NITROSATION OF A 2-METHYLACETANILIDE | TENNECO CHEMICALS, INC. (US) | 1978-06-20 | — | — | US | disclosed |
| US-3988347-A | NITROSATION OF A 2-METHYL-ACETANILIDE WITH SODIUM NITRITE | TENNECO CHEMICALS, INC. (US) | 1976-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120195857-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | NOS1 3677/4885METAP2 579/4885AXL 4133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.